Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder: HCRN GU22-598
A phase 2 trial for muscle-invasive bladder cancer using enfortumab vedotin plus pembrolizumab without the need for cystectomy or surgery.
Sponsor: Astellas Pharma, Hoosier Cancer Research Network, & Merck
Enrolling: Male and Female Patients
IRB Number: AAAV9307
U.S. Govt. ID: NCT06809140
Contact: Alexander Wei: / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if the combination of enfortumab vedotin and pembrolizumab leads to no detectable cancer on early assessments of the bladder after initial treatment. We are asking you to take part in this research study because you have muscle-invasive bladder cancer. This combination of enfortumab vedotin and pembrolizumab has been tested in people and is approved by the U.S. Food and Drug Administration (FDA) to treat patients with bladder cancer that has spread outside of the bladder (also known as metastatic bladder cancer).
Investigator
Alexander Wei, MD
Do You Qualify?
Do you have muscle-invasive bladder cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Alexander Wei
cancerclinicaltrials@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE